Orexin B (Hypocretin-2)

Orexin B, also called hypocretin-2, is a 28-amino-acid neuropeptide. It is cut from the same precursor protein as orexin A and is made by a small group of neurons in the lateral hypothalamus. These neurons act like a switch for wakefulness and arousal: active when you are awake and alert, quiet during sleep.

The orexin system was discovered in 1998 by Sakurai and colleagues, originally in the context of food intake regulation - hence the name ("orexis" is Greek for appetite). It quickly became clear that the much bigger role lies in sleep-wake regulation. In humans, loss of these orexin neurons is the core mechanism behind narcolepsy type 1.

One thing up front, and it runs through this whole entry: orexin B is a pure research peptide. It is not a medicine and has not been studied for human use - least of all as a subcutaneous injection. This information is for research and educational purposes only. No medical recommendations.

Orexin B binds to orexin receptors, of which there are two: OX1R and OX2R. Orexin B is clearly selective for OX2R - its affinity for OX1R is roughly 10 to 100-fold lower. That OX2R is tightly linked to sleep-wake control, while OX1R is more associated with motivation, reward and autonomic functions.

Through OX2R, orexin neurons activate downstream wake-promoting systems in the brain and stabilize the awake state. When orexins are missing, that switch flips uncontrollably - that is the model behind narcolepsy. The logical research idea: if orexin deficiency causes sleepiness, then OX2R agonism might do the opposite and promote wakefulness. That is exactly why orexin receptor agonism is researched for wakefulness and narcolepsy.

The crucial catch is in the next section: for orexin B to do anything in the brain, it first has to get there. And with peripheral dosing, that is the problem.

Before you start, have everything ready:

• The orexin B vial with the freeze-dried powder
• Bacteriostatic water for reconstitution
• U-100 insulin syringes for administration
• Alcohol swabs for the vial cap and the skin site
• A sealable container for used needles

Orexin B is a fragile peptide. Be careful when reconstituting and storing it, or you will end up with nothing but expensive water in the vial.

The powder is dissolved with bacteriostatic water. How much water you use sets the concentration, and that determines how many units you draw on the insulin syringe for your dose. Let the bacteriostatic water run down the inside wall of the vial rather than jetting it onto the powder, then swirl gently instead of shaking.

Use the calculator above for exactly this: pick the vial size and water volume, and you immediately see the concentration and the units per dose.

Injection is subcutaneous, into the fatty tissue under the skin. Typical sites are the abdomen (avoiding the area right around the navel), the front of the thigh, or the back of the upper arm.

• Clean the skin site with an alcohol swab and let it dry
• Pinch up a small skin fold
• Insert the needle at a 45 to 90 degree angle
• Inject slowly, wait briefly, then withdraw the needle
• Drop the needle straight into the sharps container

Rotate the injection site every time. But honestly: even a perfect subcutaneous injection leaves the central effect doubtful - the reason is right below.

Most of what is known about orexin B comes from cell systems and animal models, not humans:

• Discovery and appetite: In a rat model, centrally administered orexin increased food intake, and the peptide was upregulated during fasting (Sakurai 1998, preclinical).
• Blood-brain barrier: In mice, orexin A crossed the barrier by simple diffusion, whereas orexin B was rapidly degraded in blood and did not reach the brain intact (Kastin & Akerstrom 1999, preclinical). This is the central reality check for peripheral dosing.
• Receptor role: Reviews clearly assign OX2R, orexin B's preferred receptor, to sleep-wake control (Sun, Tisdale & Kilduff 2021).
• Narcolepsy context: Loss of orexin neurons is considered the core mechanism of narcolepsy type 1 - this supplies the logic for why orexin agonism is researched for wakefulness at all (Kornum et al. 2017).

What is missing matters just as much: there is no solid human data for peripherally injected orexin B as a wake-promoting or metabolic peptide.

Again: there is no established side-effect profile for peripherally administered orexin B in humans, simply because the application has not been studied.

• Local reactions at the injection site (redness, swelling, mild irritation) are conceivable with any subcutaneous peptide
• Since the orexin system is linked to arousal, cardiovascular function and appetite, effects on wakefulness, circulation or hunger cannot theoretically be ruled out - described in the research context, not proven for this route
• Purity and correct reconstitution are critical: poorly dissolved or contaminated material is a risk in its own right

The absence of documented side effects is not proof of safety, it is a sign of missing data.

Orexin B is one of those peptides where the theory sounds more exciting than the practice delivers. The OX2R signal is real and linked to wakefulness, that is well established. The sticking point is delivery: as a subcutaneous injection, orexin B barely reaches the brain because it is degraded too fast in blood. For a central wake effect, the peripheral injection is probably the wrong route.

Treat orexin B as what it is: an experimental research peptide with thin human data, whose peripheral benefit is open to doubtful. Anyone who wants realistic expectations should factor that in honestly.

The undissolved powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. Once reconstituted, the solution goes in the fridge (2 to 8 degrees) and keeps there for several weeks. The bacteriostatic water carries a preservative that keeps the dissolved form stable longer. Protect from light and heat, and avoid repeated freeze-thaw cycles.